Literature DB >> 27909942

Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹.

David S Bayard1, Michael Neely2,3.   

Abstract

An experimental design approach is presented for individualized therapy in the special case where the prior information is specified by a nonparametric (NP) population model. Here, a NP model refers to a discrete probability model characterized by a finite set of support points and their associated weights. An important question arises as to how to best design experiments for this type of model. Many experimental design methods are based on Fisher information or other approaches originally developed for parametric models. While such approaches have been used with some success across various applications, it is interesting to note that they largely fail to address the fundamentally discrete nature of the NP model. Specifically, the problem of identifying an individual from a NP prior is more naturally treated as a problem of classification, i.e., to find a support point that best matches the patient's behavior. This paper studies the discrete nature of the NP experiment design problem from a classification point of view. Several new insights are provided including the use of Bayes Risk as an information measure, and new alternative methods for experiment design. One particular method, denoted as MMopt (multiple-model optimal), will be examined in detail and shown to require minimal computation while having distinct advantages compared to existing approaches. Several simulated examples, including a case study involving oral voriconazole in children, are given to demonstrate the usefulness of MMopt in pharmacokinetics applications.

Entities:  

Keywords:  Bayes Risk; Experiment design; Nonparametric; Population model; Voriconazole

Mesh:

Substances:

Year:  2016        PMID: 27909942      PMCID: PMC5376526          DOI: 10.1007/s10928-016-9498-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  22 in total

1.  Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations.

Authors:  L B Sheiner; H Halkin; C Peck; B Rosenberg; K L Melmon
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

2.  The use of prior distributions in the design of experiments for parameter estimation in non-linear situations.

Authors:  N R Draper; W G Hunter
Journal:  Biometrika       Date:  1967-06       Impact factor: 2.445

3.  Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin.

Authors:  Stefanie Hennig; Joakim Nyberg; Samuel Fanta; Janne T Backman; Kalle Hoppu; Andrew C Hooker; Mats O Karlsson
Journal:  J Clin Pharmacol       Date:  2011-05-04       Impact factor: 3.126

4.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

5.  A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.

Authors:  Pavan Vajjah; Stephen B Duffull
Journal:  Pharm Stat       Date:  2012-10-12       Impact factor: 1.894

6.  Optimal experiment design for nonlinear models subject to large prior uncertainties.

Authors:  E Walter; L Pronzato
Journal:  Am J Physiol       Date:  1987-09

Review 7.  Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application.

Authors:  S Vozeh; J L Steimer
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

8.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

Review 9.  Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.

Authors:  Meinolf Karthaus; Thomas Lehrnbecher; Hans-Peter Lipp; Stefan Kluge; Dieter Buchheidt
Journal:  Ann Hematol       Date:  2015-02-20       Impact factor: 3.673

10.  Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.

Authors:  Luc J Huurneman; Michael Neely; Anette Veringa; Fernando Docobo Pérez; Virginia Ramos-Martin; Wim J Tissing; Jan-Willem C Alffenaar; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

View more
  6 in total

1.  Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients.

Authors:  Marc Labriffe; Julien Vaidie; Caroline Monchaud; Jean Debord; Pascal Turlure; Stephane Girault; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

2.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Authors:  Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients.

Authors:  Jean-Baptiste Woillard; Jean Debord; Caroline Monchaud; Franck Saint-Marcoux; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

4.  A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.

Authors:  Ida Robertsen; Jean Debord; Anders Åsberg; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

5.  An Algorithm for Nonparametric Estimation of a Multivariate Mixing Distribution with Applications to Population Pharmacokinetics.

Authors:  Walter M Yamada; Michael N Neely; Jay Bartroff; David S Bayard; James V Burke; Mike van Guilder; Roger W Jelliffe; Alona Kryshchenko; Robert Leary; Tatiana Tatarinova; Alan Schumitzky
Journal:  Pharmaceutics       Date:  2020-12-30       Impact factor: 6.321

6.  Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.

Authors:  Marte Theie Gustavsen; Karsten Midtvedt; Ida Robertsen; Jean-Baptiste Woillard; Jean Debord; Rolf Anton Klaasen; Nils Tore Vethe; Stein Bergan; Anders Åsberg
Journal:  Clin Transl Sci       Date:  2020-07-11       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.